Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SRDAN VERSTOVSEK and PRITHVIRAJ BOSE.
SRDAN VERSTOVSEK
Connection Strength
24.222
PRITHVIRAJ BOSE
  1. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 Apr 04.
    View in: PubMed
    Score: 0.997
  2. Avapritinib for Systemic Mastocytosis. Expert Rev Hematol. 2021 08; 14(8):687-696.
    View in: PubMed
    Score: 0.829
  3. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):641-649.
    View in: PubMed
    Score: 0.822
  4. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers (Basel). 2020 Oct 09; 12(10).
    View in: PubMed
    Score: 0.783
  5. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. Hemasphere. 2020 Aug; 4(4):e424.
    View in: PubMed
    Score: 0.771
  6. Management of myelofibrosis after ruxolitinib failure. Leuk Lymphoma. 2020 08; 61(8):1797-1809.
    View in: PubMed
    Score: 0.757
  7. Mutational profiling in myelofibrosis: implications for management. Int J Hematol. 2020 Feb; 111(2):192-199.
    View in: PubMed
    Score: 0.732
  8. Updates in the management of polycythemia vera and essential thrombocythemia. Ther Adv Hematol. 2019; 10:2040620719870052.
    View in: PubMed
    Score: 0.725
  9. MF management. Hemasphere. 2019 Jun; 3(Suppl).
    View in: PubMed
    Score: 0.717
  10. New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol. 2019 01 24; 20(1):5.
    View in: PubMed
    Score: 0.696
  11. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774.
    View in: PubMed
    Score: 0.694
  12. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki. 2019; 60(9):1176-1185.
    View in: PubMed
    Score: 0.693
  13. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.
    View in: PubMed
    Score: 0.679
  14. Management of Myelofibrosis-Related Cytopenias. Curr Hematol Malig Rep. 2018 06; 13(3):164-172.
    View in: PubMed
    Score: 0.665
  15. SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):1-12.
    View in: PubMed
    Score: 0.646
  16. Ruxolitinib for essential thrombocythemia? Oncoscience. 2017 Nov; 4(11-12):148-149.
    View in: PubMed
    Score: 0.639
  17. Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2017 07; 17S:S43-S52.
    View in: PubMed
    Score: 0.624
  18. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017 07 13; 130(2):115-125.
    View in: PubMed
    Score: 0.618
  19. Investigational Janus kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs. 2017 Jun; 26(6):723-734.
    View in: PubMed
    Score: 0.618
  20. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw. 2016 12; 14(12):1613-1624.
    View in: PubMed
    Score: 0.600
  21. Myelofibrosis: an update on drug therapy in 2016. Expert Opin Pharmacother. 2016 Dec; 17(18):2375-2389.
    View in: PubMed
    Score: 0.597
  22. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs. 2016 Dec; 25(12):1393-1403.
    View in: PubMed
    Score: 0.596
  23. Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S105-13.
    View in: PubMed
    Score: 0.586
  24. The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer. 2016 Mar 01; 122(5):681-92.
    View in: PubMed
    Score: 0.562
  25. Interferons in the treatment of myeloproliferative neoplasms. Ther Adv Hematol. 2024; 15:20406207241229588.
    View in: PubMed
    Score: 0.247
  26. A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial. Haematologica. 2024 Jan 25.
    View in: PubMed
    Score: 0.246
  27. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 10 10; 7(19):5835-5842.
    View in: PubMed
    Score: 0.241
  28. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol. 2023; 146(6):522-529.
    View in: PubMed
    Score: 0.240
  29. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments. Cancers (Basel). 2023 Jun 24; 15(13).
    View in: PubMed
    Score: 0.236
  30. The role of therapy in the outcome of patients with myelofibrosis. Cancer. 2023 09 15; 129(18):2828-2835.
    View in: PubMed
    Score: 0.235
  31. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023 06; 64(6):1063-1081.
    View in: PubMed
    Score: 0.233
  32. Cytopenic myelofibrosis: prevalence, relevance, and treatment. Expert Opin Pharmacother. 2023 Jun; 24(8):901-912.
    View in: PubMed
    Score: 0.233
  33. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma. 2022 11; 63(11):2701-2705.
    View in: PubMed
    Score: 0.221
  34. Disease Modification in Myelofibrosis: An Elusive Goal? J Clin Oncol. 2022 04 10; 40(11):1147-1154.
    View in: PubMed
    Score: 0.214
  35. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022 04 15; 128(8):1658-1665.
    View in: PubMed
    Score: 0.214
  36. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022 01 19; 15(1):7.
    View in: PubMed
    Score: 0.214
  37. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol. 2022; 366:83-124.
    View in: PubMed
    Score: 0.212
  38. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):210-223.
    View in: PubMed
    Score: 0.210
  39. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
    View in: PubMed
    Score: 0.208
  40. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021 04 27; 5(8):2156-2164.
    View in: PubMed
    Score: 0.203
  41. Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematol. 2021; 144(5):484-499.
    View in: PubMed
    Score: 0.203
  42. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6.
    View in: PubMed
    Score: 0.199
  43. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331.
    View in: PubMed
    Score: 0.193
  44. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs. 2020 Jun; 29(6):525-536.
    View in: PubMed
    Score: 0.193
  45. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
    View in: PubMed
    Score: 0.188
  46. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv. 2019 08 13; 3(15):2264-2271.
    View in: PubMed
    Score: 0.181
  47. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2019 08; 14(4):310-327.
    View in: PubMed
    Score: 0.180
  48. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 2019 06 01; 125(11):1855-1866.
    View in: PubMed
    Score: 0.175
  49. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018 Mar; 100(3):257-263.
    View in: PubMed
    Score: 0.162
  50. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clin Case Rep. 2018 01; 6(1):155-161.
    View in: PubMed
    Score: 0.161
  51. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131.
    View in: PubMed
    Score: 0.156
  52. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017 08; 59:110-116.
    View in: PubMed
    Score: 0.155
  53. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res. 2017 07; 58:14-22.
    View in: PubMed
    Score: 0.153
  54. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res. 2017 06; 57:85-88.
    View in: PubMed
    Score: 0.153
  55. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol. 2017 May; 96(5):733-738.
    View in: PubMed
    Score: 0.152
  56. Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Br J Haematol. 2017 Feb; 176(3):352-364.
    View in: PubMed
    Score: 0.150
  57. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma. 2017 04; 58(4):866-871.
    View in: PubMed
    Score: 0.147
  58. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
    View in: PubMed
    Score: 0.055
  59. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. 2022 06 15; 208(12):2847-2855.
    View in: PubMed
    Score: 0.055
  60. Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol. 2022 Oct; 40(4):491-504.
    View in: PubMed
    Score: 0.054
  61. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022 01 31; 12(1):23.
    View in: PubMed
    Score: 0.054
  62. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 12; 27(12):2183-2191.
    View in: PubMed
    Score: 0.053
  63. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2021 07 01; 106(7):1988-1990.
    View in: PubMed
    Score: 0.051
  64. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
    View in: PubMed
    Score: 0.051
  65. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.051
  66. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
    View in: PubMed
    Score: 0.051
  67. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.
    View in: PubMed
    Score: 0.051
  68. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. 2021 06; 193(5):1004-1008.
    View in: PubMed
    Score: 0.051
  69. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 02; 12(5):401-411.
    View in: PubMed
    Score: 0.050
  70. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
    View in: PubMed
    Score: 0.049
  71. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
    View in: PubMed
    Score: 0.048
  72. Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269.
    View in: PubMed
    Score: 0.047
  73. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
    View in: PubMed
    Score: 0.046
  74. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. 2019 Aug; 37(3):240-252.
    View in: PubMed
    Score: 0.045
  75. Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386.
    View in: PubMed
    Score: 0.043
  76. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.042
  77. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191.
    View in: PubMed
    Score: 0.041
  78. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
    View in: PubMed
    Score: 0.040
  79. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol. 2017 Feb; 4(2):e67-e74.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.